Apellis Pharmaceuticals, Inc. (APLS) NASDAQ

41.03

+0(+0.00%)

Updated at May 15 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Cedric Francois	Co-Founder, President, Chief Executive Officer & Director	1.18M	1972
Alec Machiels	Co-Founder & Director	92,500	1973
Kelley Boucher	Chief People Officer	326,383	N/A
Nur Nicholson	Chief Technical Operations Officer	373,404	1970
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	688,055	1970
David O. Watson	General Counsel & Secretary	851,115	1973
Timothy E. Sullivan	Chief Financial Officer & Treasurer	867,358	1971
Caroline R. Baumal	Chief Medical Officer	977,991	1968
Leslie Meltzer	Chief Research & Development Officer	0	N/A
Philip Ferrone	Chief Medical Retina Advisor	0	N/A
Eva Stroynowski	Head of Investor Relations	0	N/A
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	0	N/A
David L. Acheson	Executive Vice President of Commercial	0	N/A
James G. Chopas	Vice President, Corporate Controller & Chief Accounting Officer	0	1967
Mark Jeffrey DeLong	Chief Business & Strategy Officer	0	1978

Name

Title

Pay

Year Born

Cedric Francois

Co-Founder, President, Chief Executive Officer & Director

1.18M

1972

Alec Machiels

Co-Founder & Director

92,500

1973

Kelley Boucher

Chief People Officer

326,383

N/A

Nur Nicholson

Chief Technical Operations Officer

373,404

1970

Pascal Deschatelets

Co-Founder & Chief Scientific Officer

688,055

1970

David O. Watson

General Counsel & Secretary

851,115

1973

Timothy E. Sullivan

Chief Financial Officer & Treasurer

867,358

1971

Caroline R. Baumal

Chief Medical Officer

977,991

1968

Leslie Meltzer

Chief Research & Development Officer

N/A

Philip Ferrone

Chief Medical Retina Advisor

N/A

Eva Stroynowski

Head of Investor Relations

N/A

Peter Hillmen

Head of Hematology Engagement & Member of PNH Scientific Advisory Board

N/A

David L. Acheson

Executive Vice President of Commercial

N/A

James G. Chopas

Vice President, Corporate Controller & Chief Accounting Officer

1967

Mark Jeffrey DeLong

Chief Business & Strategy Officer

1978

Description

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.